Texas Arthritis Center

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lupus (SLE)5 trials
• Psoriatic arthritis2 trials
• Psoriasis1 trial

Phase

• Phase 34 trials
• Phase 11 trial
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Recruiting3 trials
• Withdrawn1 trial

Lead sponsor

• Hoffmann-La Roche2 trials
• Viatris Innovation GmbH2 trials
• Aurinia Pharmaceuticals Inc.1 trial
• Novartis Pharmaceuticals1 trial
• University of Pennsylvania1 trial

Running trials

• Recruiting

  PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

  NCT07611214· Phase 4· Aurinia Pharmaceuticals Inc.· Source

• Recruiting

  A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

  NCT07201129· Phase 3· Viatris Innovation GmbH· Source

• Recruiting

  Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

  NCT06751238· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Jose Cos

• Active, not recruiting

  Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

  NCT05669833· Phase 3· University of Pennsylvania· Source

• Active, not recruiting

  A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

  NCT05672576· Phase 3· Viatris Innovation GmbH· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

  NCT04963296· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)2 recruiting
• Psoriatic arthritis1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

  NCT05039619· Phase 2· Hoffmann-La Roche· Source